Behavioral characterization of d- and l-amphetamine: neurochemical implications.

Various doses of d- and l-amphetamine affect the temporal pattern of rat behavior in the following ways: First, the patterns of activity produced by d- and l-amphetamine are similar but out of phase; that is, the response to d-amphetamine has a relatively shorter latency whereas the effects of l-amphetamine persist for longer periods of time. Second, d-amphetamine is approximately five times as potent as l-amphetamine in its effects on both the total amount of locomotor activity and the duration of stereotypy. Both amphetamine-induced locomotion and stereotypy may be mediated by the same neurochemical mechanisms.

Thyroid state: effects on pre- and postsynaptic central noradrenergic mechanisms.

For hypothyroid rats, spontaneous motor activity was less than that in matched normal controls, and the specific activity of tyrosine hydroxylase in the midbrain was significantly greater than that in controls. Rats made hyperthyroid with thyroxine became hyperactive and showed increased sensitivity to the behaviorally activating effects of norepinephrine administered intraventricularly. In hyperthyroid rats, the specific activity of tyrosine hydroxylase in the midbrain remained within the normal range. These results are consonant with studies that suggested both receptor "tuning" and feedback regulation of activity of enzymes involved in biosynthesis of presynaptic neurotransmitter as methods of regulation of the central catecholamine synapse. These results may also help explain the reported potentiation by thyroid hormone of the antidepressant effects of imipramine.

Cycloheximide: its effects on activity are dissociable from its effects on memory.

Cycloheximide, when injected subcutaneously or intracerebrally, produces changes in the activity level of mice. Isocycloheximide, injected intracerebrally, produces identical effects on activity, but it does not produce inhibition of cerebral protein synthesis or amnesia. Amphetamine, in doses that can antagonize the amnesic action of cycloheximide, does not antagonize the effect of cycloheximide on activity. Effects of cycloheximide on activity do not appear to be responsible for its amnesic action.

Strain differences during intraventricular infusion of norepinephrine: possible role of receptor sensitivity.

Two rat strains previously shown to differ with respect to behavioral activity, regional brain tyrosine hydroxylase activity, and norepinephrine-elicited accumulation of adenosine 3', 5'-monophosphate exhibited differential behavioral responsiveness during the intraventricular infusion of norepinephrine. The results are interpreted in terms of differential catecholamine receptor sensitivity.

Multiple daily amphetamine administration: behavioral and neurochemical alterations.

In rats, multiple daily amphetamine injections (2.5 milligrams per kilogram of body weight, injected subcutaneously every 4 hours for 5 days) resulted in a progressive augmentation in response, characterized by a more rapid onset and an increased magnitude of stereotypy. By contrast, offset times of both the stereotypy and the poststereotypy hyperactivity periods were markedly shortened. When the animals were retested with the same dose of amphetamine 8 days after the long-term treatment was discontinued, the time of offset of the stereotypy and hyperactivity phases had recovered to values found with short-term amphetamine treatment, whereas the more rapid onset of stereotypy persisted. Brain monoamine and amphetamine concentrations and tyrosine hydroxylase activity were determined in comparably treated rats at times corresponding to the behavioral observations. The behavioral data indicate that enhanced responsiveness to amphetamine following its repeated administration may contribute to the development of amphetamine psychosis.

Effects of long-term reserpine treatment on brain tyrosine hydroxylase and behavioral activity.

Treatment of rats with reserpine (for 8 or 9 days) produced a temporally related increase in behavioral activity and in tyrosine hydroxylase activity in the midbrain. Weight loss resulting from such treatment was not sufficient, by itself, to account for either the behavioral or enzymatic changes. The results support the role of catecholamines in behavioral arousal.

beta-Endorphin: endogenous opiate or neuroleptic?

The opiatelike neuropeptide beta-endorphin produces a spectrum of effects that contrasts with that induced by the neuroleptic haloperidol. Rats injected intraventricularly or directly into the periaqueductal gray with beta-endorphin (0.5 to 50 micrograms) exhibited rigid immobility accompanied by the loss of righting reflex; the period of rigidity was preceded or followed (depending upon dose) by a state of hyperactivity. In contrast, no dose of haloperidol tested (0.5 to 12 milligrams per kilogram) produced rigidity, loss of righting reflex, or behavioral excitation. Furthermore, whereas animals injected with haloperidol remained stationary on a vertical grid, rats injected with beta-endorphin typically slid off the grid. Moreover, combined beta-endorphin and haloperidol treatment produced flaccidity in most animals. These results do not support the contention that this opiatelike peptide may be a naturally occurring neuroleptic.

Multiple daily amphetamine administration: behavioral and neurochemical alterations.

In rats, multiple daily amphetamine injections (2.5 milligrams per kilogram of body weight, injected subcutaneously every 4 hours for 5 days) resulted in a progressive augmentation in response, characterized by a more rapid onset and an increased magnitude of stereotypy. By contrast, offset times of both the stereotypy and the poststereotypy hyperactivity periods were markedly shortened. When the animals were retested with the same dose of amphetamine 8 days after the long-term treatment was discontinued, the time of offset of the stereotypy and hyperactivity phases had recovered to values found with short-term amphetamine treatment, whereas the more rapid onset of stereotypy persisted. Brain monoamine and amphetamine concentrations and tyrosine hydroxylase activity were determined in comparably treated rats at times corresponding to the behavioral observations. The behavioral data indicate that enhanced responsiveness to amphetamine following its repeated administration may contribute to the development of amphetamine psychosis.

Naloxone-induced behavioral and physiological effects in normal and manic subjects.

Intravenous naloxone hydrochloride (20 mg) was administered to eight normal control subjects and 12 affective disorder patients manifesting manic or hypomanic symptoms. On two consecutive days, in a counterbalanced order, naloxone and placebo were given in a double-blind crossover design. The overall effect of naloxone was to decrease pulse rate and to promote lethargy and inactivation. The normal controls manifested reduced feelings of well-being, and the manic patients noted a subjective sense of slowing. There was a variable response pattern to naloxone in the manic patients in which four of the 12 patients manifested an observable reduction in their manic symptoms and behavior after the naloxone administration. Naloxone seems to have had a nonspecific subduing effect in both normal subjects and patients and may also have had a selectively greater effect in a small subsample of the manics.

Blunted prolactin response. A neuroendocrine abnormality manifested by depressed patients.

Prolactin concentrations of 30 unmedicated psychiatric inpatients and 11 normal controls were measured at baseline and at 30 and 60 minutes after the administration of 10 mg of intramuscular methadone hydrochloride. Methadone raised the prolactin level at 60 minutes to more than twice the mean baseline level for the full subject sample. Patients with depressive disorders had lower mean basal prolactin levels than did the other subjects, and also manifested attenuated prolactin responses to methadone. Eight of 16 depressives had markedly blunted prolactin responses, a finding consistent with other studies reporting deficient responses in depression. These data are consistent with the hypothesis that the pathophysiology of depressive disorders involves dysfunctions in the anterior pituitary itself or in the hypothalamic neurotransmitter and neuromodulator systems (eg, endorphins) that regulate the secretion of prolactin and other neurohormones.

Identifying a series of candidate genes for mania and psychosis: a convergent functional genomics approach.

We have used methamphetamine treatment of rats as an animal model for psychotic mania. Specific brain regions were analyzed comprehensively for changes in gene expression using oligonucleotide GeneChip microarrays. The data was cross-matched against human genomic loci associated with either bipolar disorder or schizophrenia. Using this convergent approach, we have identified several novel candidate genes (e.g., signal transduction molecules, transcription factors, metabolic enzymes) that may be involved in the pathogenesis of mood disorders and psychosis. Furthermore, for one of these genes, G protein-coupled receptor kinase 3 (GRK3), we found by Western blot analysis evidence for decreased protein levels in a subset of patient lymphoblastoid cell lines that correlated with disease severity. Finally, the classification of these candidate genes into two prototypical categories, psychogenes and psychosis-suppressor genes, is described.

Behavioral activating effects of opiates and opioid peptides.

Locomotor activity of rats and mice was monitored following administration of the opiates, morphine, methadone, and etonitazene, or the opioid peptides, beta-endorphin, D-Ala2-Met5-enkephalinamide, and D-Met2-Pro5-enkephalinamide. In rats these agents produced dose-related biphasic patterns of activity consisting of an initial depression in locomotion followed by a period of hyperactivity. Intravenous administration of morphine, methadone, or etonitazene in mice produced dose-related increases in stereotyped locomotor activity. The metabolically resistant enkephalin analog, D-Met2-Pro5-enkephalinamide induced a similar pattern of effects. However, doses of beta-endorphin up to 20 mg/kg, iv, failed to elicit locomotor stimulation in mice. The similarity in the naloxone-reversible responses induced by opiates and certain opioid peptides suggests that the same underlying mechanisms may subserve their behavioral effects.

The effects of phencyclidine on spontaneous aggressive behavior in the rat.

Phencyclidine induced dose-related alterations in the pattern of spontaneous aggressive behavior in pairs of rats, in which only one animal of each pair was drug-treated. At the lowest dose tested (0.25 mg/kg, sc), phencyclidine produced attacks by the drug-treated animal and a corresponding increase in submissive behavior by the untreated partner, as well as an increase in boxing behavior by both animals. In contrast, the highest dose of phencyclidine tested (1.0 mg/kg, sc) elicited attacks and allogrooming by the untreated animal. The low dose effect is interpreted as the result of phencyclidine-induced distortion in perception of social cues, while the high dose effect may be due to a general disruption in social communication by ataxia in the phencyclidine-treated animal.

Repeated amphetamine and fencamfamine: sensitization and reciprocal cross-sensitization.

The repeated administration of amphetamine and related dopamine agonists results in an augmented or sensitized behavioral response to subsequent administration of these drugs. In addition to reflecting central nervous system plasticity, this altered response profile may also represent an animal model for stimulant-induced psychosis in humans. Therefore, considerable interest has been focused on determining the mechanisms underlying the sensitization process. One approach involves comparing and contrasting the effects of various stimulants possessing different molecular mechanisms of action. In this regard, some evidence suggests that fencamfamine and amphetamine interact with pharmacologically distinguishable dopamine pools. Therefore, we compared the behavioral response profiles to the repeated administration of behaviorally comparable doses of amphetamine and fencamfamine, and examined the pattern of cross-interaction between the two stimulants. Fencamfamine produced an amphetamine-like pattern of behavioral augmentation, and both drugs exhibited identical patterns of cross-sensitization. These results lend further support to the sensitization model of stimulant psychosis. Possible dopaminergic mechanisms underlying the sensitization are discussed.

Differential regional zif268 messenger RNA expression in an escalating dose/binge model of amphetamine-induced psychosis.

Amphetamine-induced psychosis is most often associated with a high-dose multiple binge pattern of stimulant abuse. To simulate these conditions in rats, we used an escalating dose/binge administration paradigm. Animals were pretreated with escalating doses of amphetamine (1.0-8.0mg/kg) over four days, then exposed to nine daily binges (8.0mg/kg every 2h; four injections/day). Other animals received either multiple injections of saline, saline followed by acute amphetamine (8.0mg/kg) or single daily injections of amphetamine (8.0mg/kg) in parallel with the escalating dose/binge treatment. One hour after the last injection, all animals were decapitated and regional brain activation patterns were assessed using in situ hybridization with antisense probes for zif268. Acute amphetamine resulted in a significant elevation of zif268 messenger RNA in both the nucleus accumbens and dorsal striatum. However, whereas after single daily amphetamine treatment this index was no longer elevated above control levels in the dorsal striatum, multiple binge exposures were required for the nucleus accumbens to return to baseline. Agranular insular cortex and medial olfactory tubercle zif268 messenger RNA expression was also markedly increased after acute amphetamine treatment but, unlike the nucleus accumbens and dorsal striatum, this increase was not significantly attenuated by either single daily injection or multiple binge treatment. Zif268 messenger RNA expression in the lateral nucleus of the amygdala also remained elevated above baseline after binge treatment. The possible relationships of these changes in zif268 messenger RNA regional expression patterns to the development of psychosis in high-dose stimulant abusers are discussed.

Hippocampal glucocorticoid receptor mRNA is up-regulated by acute and down-regulated by chronic amphetamine treatment.

Repeated administration of amphetamine-like stimulants to rats results in enhanced behavioral responsiveness to subsequent administration of these drugs. Recent evidence suggests corticosterone may play a role in the development of sensitization perhaps through the down-regulation of glucocorticoid receptor (GR). To test this hypothesis further we examined the effects of five daily injections of amphetamine (AMPH) (2.5 mg/kg) on GR mRNA of adult Sprague-Dawley rats. Two other groups received saline for 4 days and then either saline or AMPH on the fifth day. All animals were killed 24 h after the last treatment and in situ hybridization was performed with an antisense mRNA GR probe. Quantification of hippocampal GR was accomplished by computer analysis of digitized images of CA1 and dentate gyrus. Acute AMPH produced a significant up-regulation of GR mRNA in CA1 and a nonsignificant trend towards up-regulation in the dentate gyrus. Repeated exposure to AMPH resulted in a significant down-regulation in CA1, and a nonsignificant trend towards down-regulation in dentate gyrus. These data support a role for hippocampal GR mRNA in the development of behavioral sensitization.

Regional quantification of D1, D2, and D3 dopamine receptor mRNA in rat brain using a ribonuclease protection assay.

We describe ribonuclease protection assays for dopamine D1, D2, and D3 receptors, and regional quantitation of mRNA levels for these receptors in rat brain. Both D1 and D2 mRNA levels were highest in caudate putamen, where they were found in approximately equal levels. Of the brain regions examined, D3 mRNA was most abundant in hippocampus, hypothalamus, and nucleus accumbens. Levels of D3 mRNA were significantly lower than values for D1 and D2 mRNA in all brain regions studied. Variability was observed between animals for expression of both D1 and D2 mRNA in caudate putamen, with a significant correlation between D1 and D2 mRNA levels in neostriatum (r = 0.942, P < 0.001). This suggests a functional interaction between D1 and D2 receptor mRNA levels in this brain region. Our results are generally consistent with regional distributions previously reported using other methods. These results suggest that DA D2 receptors function both as an auto and as a postsynaptic receptor, while D1 receptors are restricted to a postsynaptic function. Our results demonstrate the utility of this method in studying possible relationships between individual animal variation in regional mRNA expression and behavioral response to pharmacological and other experimental treatments.

Does dizocilpine (MK-801) selectively block the enhanced responsiveness to repeated amphetamine administration?

In order to examine the hypothesis that N-methyl-D-aspartate (NMDA) receptors are selectively involved in the development of stimulant sensitization, we characterized the interaction between acute and chronic dizocilpine (MK-801) + amphetamine using a detailed behavioral analysis, including concurrent assessment of the locomotor and stereotype components of the stimulant response and continuous monitoring of all the various phases of the emergent sensitization. The results showed that MK-801 (0.125 mg/kg) significantly affected the acute response to amphetamine (0.5, 1.75, 4.0 mg/kg), increasing or decreasing locomotor activity depending on dose. Repeated administration of MK-801 + amphetamine resulted in a suppression of stereotyped behaviors and a potentiated locomotor sensitization. These findings suggest that rather than blocking the development of sensitization, MK-801 pretreatment may produce a unique behavioral augmentation that is apparent during coadministration and that persists up to 48 hr in the response to amphetamine challenge.

Antidromically identified striatonigral projection neurons in the chronically implanted behaving rat: relations of cell firing to amphetamine-induced behaviors.

The effects of systematically administered amphetamine (0.25-5.0 mg/kg, sc) on neostriatal neurons recorded in chronically implanted behaving rats were studied. Projection neurons, identified by antidromic activation from the substantia nigra, fired very infrequently during most predrug behaviors (e.g., median rate, 0.02 spikes per second during locomotion; 17 of 18 fired less than 1 spike per second during all rated behaviors). Nonantidromic cells also tended to fire slowly (median rate, 0.02 spikes per second during locomotion; 20 of 24 cells fired less than 1 spike per second). Cells of both type showed up to 10-fold variations in firing rate across behaviors. For most neurons, amphetamine caused a reduction in the firing rate during related pre- and postdrug behaviors. For instance, the firing rate of 28 of 42 neurons was reduced during the initial amphetamine-induced locomotion as compared with the rate during predrug locomotion. Moreover, with the higher doses of amphetamine, there was a further reduction in firing rate corresponding to the transition from locomotion to stereotypies. In contrast to previous studies, which suggest that amphetamine generally increases neostriatal firing rate in behaving animals, these results suggest that amphetamine inhibits the numerous slowly firing neostriatal neurons, many of which were identified as projection neurons. Thus amphetamine alters the magnitude and pattern of neostriatal control of its neural targets.

Evidence for multiple opiate receptor involvement in different phencyclidine-induced unconditioned behaviors in rats.

Rats were used for comparing the behavioral response profiles of phencyclidine (PCP) and d,1-N-allylnormetazocine (NANM), two drugs that are proposed to exert their effects through the "PCP/sigma" receptor. Phencyclidine (1.0-5.0 mg/kg) and NANM (2.5-10.0 mg/kg) induced dose-related increases in locomotion, sniffing, repetitive head movements, non-object directed mouth movements, and ataxia. Both drugs also increased food and water consumption during the latter portion of the drug response. Ingestive behaviors induced by PCP (2.5 mg/kg), as with eating and drinking stimulated by the mu-opiate morphine (2.0 mg/kg), were blocked by a relatively low dose of the opiate antagonist naloxone (0.5 mg/kg). Multiple injections of PCP (2.5 mg/kg for 4 days) or NANM (10.0 mg/kg for 4 days) augmented several measures of behavioral activation, including horizontal locomotion, rearing, and nonfocused sniffing, but did not significantly change stereotyped behaviors or ataxia. Reciprocal cross-sensitization of locomotor activation is indicated by the finding that the response to a challenge injection of PCP (2.5 mg/kg) or to NANM (10.0 mg/kg) after 4 days of treatment with the other drug closely resembled the enhanced locomotor response observed after the chronic treatment. Phencyclidine and NANM thus appear to exert many of their effects on unconditioned behavior through common mechanisms, including interaction with sigma receptors. In addition, these findings are consistent with previous suggestions that a mu-opiate receptor system may modulate some effects of PCP.